Does the media favor AMGN or REGN?

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Amgen and 27 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 0.67 beat Regeneron Pharmaceuticals' score of 0.67 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 22 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GILD or REGN?

In the previous week, Gilead Sciences had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Gilead Sciences and 27 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.82 beat Regeneron Pharmaceuticals' score of 0.67 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 24 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRNA or REGN?

In the previous week, Moderna had 32 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 59 mentions for Moderna and 27 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Moderna's score of 0.58 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 17 Very Positive mention(s) 15 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive Regeneron Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or VIR?

In the previous week, Vir Biotechnology had 31 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Vir Biotechnology and 27 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Vir Biotechnology's score of 0.56 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 12 Very Positive mention(s) 11 Positive mention(s) 24 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$955.47 +4.28 (+0.45%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$957.03 +1.56 (+0.16%)

As of 11/13/2026 07:55 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? Regeneron Pharmaceuticals's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.4%. Amgen pays out 58.5% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 8.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Amgen currently has a consensus target price of $424.66, suggesting a potential downside of 8.81%. Regeneron Pharmaceuticals has a consensus target price of $898.97, suggesting a potential downside of 5.91%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	18 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.30
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	6.85	$7.71B	$17.24	27.01
Regeneron Pharmaceuticals	$14.34B	6.89	$4.50B	$45.29	21.10

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Amgen and 27 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 0.67 beat Regeneron Pharmaceuticals' score of 0.67 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	22 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Amgen's net margin of 24.14%. Amgen's return on equity of 114.99% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	24.14%	114.99%	13.47%
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%

Summary

Amgen beats Regeneron Pharmaceuticals on 10 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Gilead Sciences presently has a consensus target price of $171.07, suggesting a potential upside of 1.78%. Regeneron Pharmaceuticals has a consensus target price of $898.97, suggesting a potential downside of 5.91%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.0%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.4%. Gilead Sciences pays out -103.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 8.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Gilead Sciences had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Gilead Sciences and 27 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.82 beat Regeneron Pharmaceuticals' score of 0.67 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	24 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Gilead Sciences' net margin of -12.47%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-12.47%	-1.85%	-0.61%
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gilead Sciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	7.08	$8.51B	-$3.16	N/A
Regeneron Pharmaceuticals	$14.34B	6.89	$4.50B	$45.29	21.10

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 13 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Moderna has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Moderna currently has a consensus price target of $113.75, indicating a potential downside of 49.08%. Regeneron Pharmaceuticals has a consensus price target of $898.97, indicating a potential downside of 5.91%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.08
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	46.49	-$2.82B	-$7.10	N/A
Regeneron Pharmaceuticals	$14.34B	6.89	$4.50B	$45.29	21.10

In the previous week, Moderna had 32 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 59 mentions for Moderna and 27 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Moderna's score of 0.58 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	17 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Moderna's net margin of -110.46%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-110.46%	-25.79%	-15.85%
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Intellia Therapeutics currently has a consensus price target of $21.44, indicating a potential upside of 121.08%. Regeneron Pharmaceuticals has a consensus price target of $898.97, indicating a potential downside of 5.91%. Given Intellia Therapeutics' higher possible upside, research analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.33
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	20.12	-$412.69M	-$3.35	N/A
Regeneron Pharmaceuticals	$14.34B	6.89	$4.50B	$45.29	21.10

In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 27 mentions for Regeneron Pharmaceuticals and 25 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Intellia Therapeutics' score of -0.12 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Intellia Therapeutics' net margin of -805.75%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-805.75%	-64.74%	-50.72%
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%

Intellia Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Vir Biotechnology had 31 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Vir Biotechnology and 27 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Vir Biotechnology's score of 0.56 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	12 Very Positive mention(s)	11 Positive mention(s)	24 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Vir Biotechnology's net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%
Vir Biotechnology	N/A	-21.38%	-16.97%

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	6.89	$4.50B	$45.29	21.10
Vir Biotechnology	$68.56M	24.88	-$437.99M	-$1.26	N/A

Regeneron Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Regeneron Pharmaceuticals currently has a consensus target price of $898.97, suggesting a potential downside of 5.91%. Vir Biotechnology has a consensus target price of $22.57, suggesting a potential upside of 126.62%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74
Vir Biotechnology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$98.40B	$4.12B	$7.84B	$12.20B
Dividend Yield	0.40%	3.62%	2.46%	4.53%
P/E Ratio	21.10	25.96	34.61	27.67
Price / Sales	6.89	16.64	8.75	5.83
Price / Cash	22.66	26.37	21.93	22.49
Price / Book	2.95	4.00	4.35	3.76
Net Income	$4.50B	-$22.78M	$3.51B	$390.55M
7 Day Performance	5.65%	-2.85%	-1.50%	-0.33%
1 Month Performance	22.75%	-3.75%	-2.56%	-4.82%
1 Year Performance	37.78%	-1.56%	0.92%	-5.83%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	3.8753 of 5 stars	$955.47 +0.4%	$898.97 -5.9%	+37.5%	$98.40B	$14.34B	21.10	15,410
AMGN Amgen	3.8917 of 5 stars	$478.48 +3.7%	$411.31 -14.0%	+38.6%	$258.68B	$36.75B	29.74	31,500	Trending News Analyst Forecast
GILD Gilead Sciences	3.4157 of 5 stars	$174.48 +4.2%	$170.15 -2.5%	+34.2%	$216.41B	$29.44B	N/A	17,000	Trending News Analyst Forecast Analyst Revision
MRNA Moderna	1.5583 of 5 stars	$258.38 +13.1%	$107.10 -58.5%	+794.9%	$103.16B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Revision Gap Down
NTLA Intellia Therapeutics	2.5479 of 5 stars	$12.31 +3.8%	$20.57 +67.1%	+11.9%	$1.73B	$67.67M	N/A	377	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Is AMGN or REGN a better dividend stock?

Which has more volatility and risk, AMGN or REGN?

Do analysts recommend AMGN or REGN?

Which has stronger earnings & valuation, AMGN or REGN?

Do insiders and institutionals have more ownership in AMGN or REGN?

Does the media favor AMGN or REGN?

Is AMGN or REGN more profitable?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Do analysts rate GILD or REGN?

Is GILD or REGN a better dividend stock?

Does the media prefer GILD or REGN?

Is GILD or REGN more profitable?

Do insiders & institutionals have more ownership in GILD or REGN?

Which has more risk and volatility, GILD or REGN?

Which has better earnings & valuation, GILD or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Which has more risk and volatility, MRNA or REGN?

Do analysts rate MRNA or REGN?

Do insiders & institutionals believe in MRNA or REGN?

Which has better valuation and earnings, MRNA or REGN?

Does the media prefer MRNA or REGN?

Is MRNA or REGN more profitable?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do analysts rate NTLA or REGN?

Which has better valuation and earnings, NTLA or REGN?

Does the media prefer NTLA or REGN?

Is NTLA or REGN more profitable?

Which has more risk and volatility, NTLA or REGN?

Do insiders & institutionals believe in NTLA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Does the media refer more to REGN or VIR?

Is REGN or VIR more profitable?

Which has preferable valuation and earnings, REGN or VIR?

Which has more volatility & risk, REGN or VIR?

Do analysts rate REGN or VIR?

Do insiders & institutionals have more ownership in REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools